News

There’s a moment most generalist tech recruiters hit when they’re working a medtech brief. It usually comes about three days in, when they’ve sent over a shortlist of candidates who look, on paper, impressive — strong engineering backgrounds, solid pedigree, great culture fit. Then the hiring manager asks a simple question: “Do any of them have experience working under ISO 13485?”

Silence.

That moment is where the gap between generalist and specialist becomes impossible to ignore.

I spent years writing about regulated industries before I ever worked inside them. I knew the terminology — FDA, CE marking, quality management systems — but I understood it the way you understand a foreign city from a guidebook. Descriptive, not lived. When I eventually moved into recruitment, specifically into medical devices and digital health, I had to unlearn almost everything I thought I knew about placing talent.

Because hiring for regulated healthcare is not a variation of tech recruitment. It’s a different discipline entirely.

The regulatory layer changes everything

In most tech sectors, a strong engineer is a strong engineer. You assess fundamentals, cultural alignment, growth trajectory. Regulated healthcare doesn’t work like that.

A software developer working on a Class II medical device is operating under FDA 21 CFR Part 820, or under EU MDR if they’re building for the European market. Their code is a regulated output. Their documentation is part of a technical file that may one day be scrutinised by a Notified Body. Their decisions have traceability requirements.

ISO 13485 — the quality management standard for medical devices, isn’t a nice-to-have on a CV. It shapes how teams are structured, how design changes are controlled, how non-conformances are managed. A candidate who’s only ever worked in unregulated environments doesn’t just have a skills gap. They have a mindset gap. Bridging it takes time that most medical device companies simply don’t have.

The same applies to clinical environments. Recruiting for a role that sits inside or adjacent to a hospital, a clinical trial, or a diagnostic pathway requires understanding care workflows, patient safety obligations, and the realities of working alongside clinicians. A recruitment process that doesn’t account for this will produce candidates who are technically qualified and practically misplaced.

Why generalist recruiters struggle

It’s not incompetence. Most generalist recruiters are genuinely good at what they do. The problem is that regulated healthcare has a vocabulary, a set of pressures, and a talent pool that sit outside the mainstream tech market.

They don’t know which candidates have worked under a Design History File versus those who’ve simply mentioned “documentation” on a LinkedIn profile. They can’t distinguish between a regulatory affairs professional who files 510(k) submissions and one who handles post-market surveillance. They struggle to evaluate whether a quality engineer’s experience maps to your specific device classification and intended use.

That knowledge takes time to build. You only build it by immersion.

What specialist recruitment actually looks like

It means knowing the community, the candidates who move between diagnostics companies and digital therapeutics startups, the quality leads who’ve navigated both FDA and EU MDR transitions, the clinical affairs professionals who’ve run studies across multiple jurisdictions.

It means being able to ask the right questions during candidate assessment. And it means being a credible counterpart to hiring managers who have neither the time nor the patience to explain regulatory context from scratch.

The talent exists. Finding it, and placing it well, is a different kind of work.

You’ve built something real. Your device works. You have clinical evidence, a growing team, and investors who believe in the vision. Now comes the next chapter: the United States.

It’s the largest medical device market in the world. It’s also one of the hardest to crack, not because of the science, but because of the people you need to hire to get there.

European MedTech founders consistently underestimate this. The US market isn’t just bigger. It operates differently, thinks differently, and rewards a very specific kind of expertise. Getting your hiring right from the start can be the difference between a successful expansion and an expensive detour.

Here’s where the real challenges tend to show up.

Finding FDA Regulatory Talent Is Harder Than You Think

Your CE mark got you this far. But the FDA is a different animal entirely and the talent that understands it deeply is in short supply.

Experienced regulatory affairs professionals with genuine FDA submission experience are scarce, expensive, and in high demand. The ones who know their way around a 510(k) or PMA process are often already embedded in established companies, well-compensated, and not actively looking.

What makes this harder for European companies is credibility. US regulatory talent wants to know that leadership understands the process, that the budget is real, and that the company is serious about the market. If any of those signals are unclear, the best candidates will choose a safer option.

The lesson: start your regulatory hiring conversation early — often before you think you need to. And be prepared to pay US market rates, which will likely surprise you.

US Commercial Leadership Is a Different Profile

Hiring a VP of Sales or Chief Commercial Officer who has thrived in Europe will not automatically translate. The US healthcare sales environment has its own rhythms, relationships, and expectations.

The best US commercial leaders for MedTech typically bring a mix of things that are hard to find together: deep relationships with hospital systems or IDNs (Integrated Delivery Networks), an understanding of how purchasing decisions actually get made, and the ability to build a team from scratch in an ambiguous, fast-moving environment.

Founders often make one of two mistakes here. The first is hiring someone too junior to open the right doors. The second is hiring a big-name executive from a large MedTech corporation who has never operated without significant infrastructure and support.

What you actually need is someone who has scaled something before — ideally in a company at a similar stage to yours, in a comparable clinical space. Those people exist, but finding them requires knowing where to look.

Clinical Adoption Requires People Who Speak the Language

In the US, getting a device into a hospital is one thing. Getting clinicians to actually use it, consistently, at volume is another challenge entirely.

Clinical adoption roles, whether that’s clinical specialists, clinical educators, or medical science liaisons, require people who can sit comfortably in a cath lab, an OR, or a cardiology department and be taken seriously. They need to understand the clinical workflow, the physician mindset, and the practical realities of how new technology gets integrated into daily practice.

This is not a role you can fill with enthusiasm alone. The candidates who perform best here typically have hands-on clinical backgrounds combined with a genuine commercial sensibility. They’re relatively rare, and they’re often hired away quickly.

Reimbursement Knowledge Is Non-Negotiable

If there’s one area where European founders consistently have a blind spot, it’s US reimbursement.

The US system — Medicare, Medicaid, commercial payers, coding, coverage, and payment is genuinely complex. Without someone on your team who understands it, you risk building a commercial strategy on a foundation that doesn’t hold up.

Reimbursement expertise isn’t just a regulatory or finance function. It shapes how you price, how you position, and how you sell. Physicians and hospital administrators will ask about it directly. If your team can’t answer confidently, it creates doubt.

Hiring for this early — even if it’s a fractional or advisory role to begin with — sends the right signal and protects you from costly assumptions.

What This Means in Practice

Expanding to the US is one of the most exciting and demanding things a MedTech founder can do. The hiring challenges are real, but they’re not insurmountable.

The companies that get it right tend to do a few things consistently: they start conversations earlier than feels necessary, they’re honest about what they don’t know, and they invest in finding people who have done this before — not just people who look good on paper.

The US market rewards preparation. And preparation, in this context, starts with the right team.

Most MedTech startups don’t fail because the science stops working. They fail because they can’t hire fast enough after the money arrives.

That’s not a headline. That’s a pattern I’ve watched play out more times than I’d like to count.

The post-funding illusion

Founders often assume that a Series A or B announcement changes their position in the talent market. In consumer tech, it does. Engineers move toward momentum. Capital signals safety.

In MedTech, experienced candidates read a funding round differently. They’re not asking how much you raised. They’re asking what device class you’re in, what your regulatory pathway looks like, whether you’ve started your technical file, and what your realistic timeline to first submission is. They’re performing due diligence on you — because they’ve seen well-funded startups collapse under regulatory pressure before, and they have no interest in being part of that story.

This is the first thing most founders get wrong. The announcement doesn’t do the work for you.

The talent pool is smaller than your model assumes

Let’s be specific about what post-funding MedTech hiring actually requires.

A Quality Director who has built a QMS from the ground up under ISO 13485 — not just maintained one. A Head of Regulatory Affairs who can navigate FDA 510(k) or PMA pathways and EU MDR simultaneously, and understands how those frameworks interact with your intended use. A Clinical Operations lead who has managed studies to ICH-GCP standards and understands site governance, data integrity obligations, and the realities of working within NHS or hospital-system constraints.

These are not interchangeable profiles. They are not abundant. And they are almost never actively looking.

The subset of candidates who have done this work, at the right device class, in a startup environment rather than a large OEM, is genuinely small. When you’re competing for them against better-known names with longer runways, the quality of your process — your brief, your timeline, your ability to present a credible regulatory narrative — determines whether you even get a conversation.

The window is shorter than you think

Post-funding momentum has a half-life. There’s a narrow period — typically eight to twelve weeks after close — where your story is fresh, candidates are curious, and the conditions for a strong hire are most favourable. Founders who wait until the ink is dry to think about recruitment consistently lose that window.

The ones who hire well engage their recruitment partners before the announcement. They arrive at market with a defined brief, a clear regulatory context, and a process designed to move at pace without cutting corners on assessment.

The bottleneck is almost never the market

There is enough specialist talent in MedTech to meet most post-funding hiring needs. What’s scarce isn’t the people, it’s hiring processes built for this environment. Generic job briefs, slow internal approvals, and interview panels that can’t speak credibly to regulatory experience will lose you the candidates you most need to attract.

The market will respond to the right approach. The question is whether your process deserves it.

The narrative around startup failure is usually clean. The market wasn’t ready. The technology didn’t scale. The unit economics never worked. These are comfortable explanations — board-level language that holds up in retrospect.

The messier truth is that a significant number of venture-backed HealthTech companies fail for reasons that were visible much earlier, and almost entirely preventable. They just weren’t treated as strategic problems until they became terminal ones.

Here are three patterns that appear, with uncomfortable regularity, across MedTech, digital health, clinical AI, and diagnostics.

---

1. The founding team scales the technology. Nobody scales the regulatory function.

Early-stage HealthTech companies are almost always built around a clinical or technical insight. The founding team is strong on science, strong on product, and entirely focused on proving the core hypothesis. Regulatory affairs is treated as a downstream concern — something to address once the technology is validated.

This is where the timeline begins to slip.

FDA submissions, EU MDR compliance, ISO 13485 implementation — these are not processes you bolt on at Series B. They require dedicated expertise, embedded early, with enough runway to build the infrastructure properly. Companies that hire their first regulatory lead twelve months too late routinely find themselves renegotiating investor timelines, repeating development cycles, and losing ground to competitors who made the hire when it was uncomfortable rather than urgent.

Regulation isn’t a milestone. It’s a capability. Building it late is one of the most expensive decisions a HealthTech founder can make.

---

2. The leadership team is built for the last stage, not the next one.

There’s a specific failure mode that emerges around Series A and B — the company has outgrown its founding team structure, but nobody wants to say it out loud. The VP of Clinical who was exceptional at running a 20-person pilot is now responsible for a multi-site study across three health systems. The Head of Quality who built the QMS in a startup environment is now managing a team of eight and reporting to a board with audit expectations.

These aren’t performance failures. They’re scope mismatches. And the cost of not addressing them — in delayed studies, quality escapes, and regulatory findings — compounds quietly until it becomes a crisis.

The strongest HealthTech leadership teams are built with the next eighteen months in mind, not the last eighteen.

---

3. Hiring slows down exactly when it needs to accelerate.

Post-funding hiring in regulated healthcare is genuinely hard. The candidates who matter — experienced regulatory affairs professionals, quality directors with device-class-specific backgrounds, clinical operations leads who’ve worked within NHS or hospital-system constraints — are not actively looking, and they are not persuaded by a LinkedIn message and a pitch deck.

When founding teams underestimate this, they lose months. The process starts too late, moves too slowly, and produces candidates who look right on paper but lack the specific regulatory context the role demands.

The window after a funding close is narrow. The startups that use it well treat hiring as a strategic function from day one — not an operational task that follows everything else.

---

These aren’t edge cases. They’re the pattern. And in an industry where regulatory timelines are unforgiving and investor patience is finite, the margin for getting team-building wrong is smaller than most founders realise until it’s too late.